Research Analysts’ Weekly Ratings Changes for Bolt Biotherapeutics (BOLT)

Several brokerages have updated their recommendations and price targets on shares of Bolt Biotherapeutics (NASDAQ: BOLT) in the last few weeks:

• 10/24/2025 – Bolt Biotherapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 10/22/2025 – Bolt Biotherapeutics was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 10/20/2025 – Bolt Biotherapeutics was given a new $7.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
• 10/20/2025 – Bolt Biotherapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $7.00 price target on the stock.
• 10/8/2025 – Bolt Biotherapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Bolt Biotherapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.